Latest filing published 20 Mar 2023 for CytomX Therapeutics, Inc., €3,269.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Carlos Campoy: trading record in brief
All filings by Carlos Campoy on record concern CytomX Therapeutics, Inc., in the capacity of finance chief. Between 30 November 2020 and 16 March 2023, the trades on record add up to 6 filings.
No open-market purchase appears, only 2 sales worth €8,776. Besides market trades, the filings include 4 share grants. 2023 to date brings no purchases and 1 sale.
The latest filing, published on 20 March 2023, reports an open-market sale of €3,269 in CytomX Therapeutics, Inc. Typically, a trade is published a median of 3 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Carlos Campoy
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,748 shares@ US$1.97919.0% of flowCommon StockSEC:0001140361-23-012617:0
- 15,000 shares0Common StockSEC:0001567619-22-014296:0
- 22,500 shares0Common StockSEC:0001567619-22-002522:0
- 3,320 shares@ US$6.08683.5% of flowCommon StockSEC:0001567619-21-011807:0
4 of 4 declarations